Key Takeaways
- Eli Lilly’s investigational triple-receptor medication retatrutide achieved its primary endpoints in a Phase 3 Type 2 diabetes study
- The drug reduced HbA1c levels by 1.7%–2% compared to 0.8% with placebo over a 40-week period
- Participants experienced weight reductions of up to 16.8% on the maximum dosage
- Unlike existing therapies, retatrutide activates three hormone pathways (GLP-1, GIP, and glucagon)
- The pharmaceutical company hasn’t submitted regulatory applications yet; seven additional Phase 3 studies will report data this year
Eli Lilly revealed Thursday that its investigational compound retatrutide successfully achieved primary efficacy measures in its inaugural late-stage diabetes study, demonstrating meaningful reductions in glucose levels alongside substantial weight loss among Type 2 diabetes participants.
Eli Lilly’s experimental weight-loss drug retatrutide met the primary and key secondary endpoints in a trial, showing significant reductions in weight loss and blood sugar levels. https://t.co/OFBUzypgGt
— The Wall Street Journal (@WSJ) March 19, 2026
The clinical trial, spanning 40 weeks, enrolled Type 2 diabetes patients who were controlling their condition solely through lifestyle modifications. Participants began the study with baseline HbA1c measurements ranging from 7% to 9.5%.
Across various dosing regimens, retatrutide demonstrated HbA1c reductions averaging between 1.7% and 2%, significantly outperforming the placebo group’s 0.8% reduction. These results satisfied the study’s predetermined primary efficacy endpoint.
Regarding body composition changes, participants receiving the maximum dose experienced an average weight reduction of 16.8% among those who completed the treatment protocol. When analyzing the full intention-to-treat population—including individuals who discontinued therapy—the average weight loss stood at 15.3%.
By comparison, Lilly’s commercially available medication Zepbound produced weight reductions between 11% and 13.1% in similar 40-week diabetes trials. While retatrutide’s weight loss figures appear superior, direct comparative studies between the two medications haven’t been conducted.
Louise Chen, an analyst at Scotiabank, characterized the findings as representing “the highest levels of weight loss we’ve seen from an obesity drug to date” within a patient demographic known for weight management challenges.
Analysts from J.P. Morgan provided a more cautious interpretation, pointing out that the drug’s efficacy gains must be weighed against increased adverse event frequencies relative to Lilly’s diabetes medication Mounjaro.
Retatrutide’s Mechanism of Action
Retatrutide is administered as a weekly subcutaneous injection that engages three distinct hormone receptor systems—GLP-1, GIP, and glucagon—prompting some to dub it a “triple-G” therapy. This represents one additional receptor target compared to Zepbound (tirzepatide), which modulates GLP-1 and GIP, and two more than Novo Nordisk‘s Wegovy (semaglutide), which exclusively activates GLP-1.
The therapeutic strategy behind targeting all three pathways simultaneously involves appetite suppression, glucose regulation, and enhanced metabolic expenditure.
Adverse reactions were predominantly gastrointestinal in nature. Approximately 26.5% of participants receiving the highest dose reported nausea, while 22.8% experienced diarrhea and 17.6% had vomiting episodes. Treatment discontinuations due to adverse effects reached a maximum of 5%, which Lilly characterized as comparatively modest.
A minority of trial participants developed dysesthesia—an abnormal, uncomfortable nerve sensation.
Regulatory Timeline and Next Steps
Lilly has not yet submitted marketing authorization applications for retatrutide in either obesity or diabetes indications. Thursday’s announcement represents only the second Phase 3 data disclosure for this investigational compound.
The pharmaceutical company anticipates releasing findings from seven more Phase 3 clinical trials throughout 2025, encompassing diverse patient populations.
Separately, Lilly is preparing to introduce its oral obesity medication orforglipron during the second quarter of this year, contingent upon FDA authorization.
Meanwhile, Novo Nordisk is pursuing competitive strategies. In March 2025, Novo acquired rights to a triple-receptor compound from United Laboratories International for up to $2 billion—though that candidate remains in early-stage development and won’t reach patients for several years.
Shares of Eli Lilly (LLY) traded marginally lower in premarket hours Thursday following the data release.
